Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2024 Earnings Conference Identify November 6, 2024 4:30 PM ET
Agency Contributors
Ryan Asay – Senior Vice President-Firm Affairs
Mark Goldsmith – Chairman and Chief Authorities Officer
Steve Kelsey – President-Evaluation and Development
Jack Anders – Chief Financial Officer
Wei Lin – Chief Medical Officer
Conference Identify Contributors
Peter Lawson – Barclays
Michael Schmidt – Guggenheim Securities
Jay Olson – Oppenheimer
Marc Frahm – TD Cowen
Alec Stranahan – Monetary establishment of America
Jonathan Chang – Leerink Companions
Eric Joseph – J.P. Morgan
Laura Prendergast – Raymond James
Operator
Good day and thanks for standing by. Welcome to Revolution Medicine’s Q3 2024 Earnings Conference Identify. In the mean time, all members are in a listen-only mode. After the speaker’s presentation, there shall be a question-and-answer session. [Operator Instructions] Please be prompt that as we communicate’s conference is being recorded.
I’d now like at hand the conference over to your first speaker as we communicate, Ryan Asay, Senior Vice President of Firm Affairs. Please go ahead.
Ryan Asay
Thanks, and welcome, all people, to the third quarter 2024 earnings title. Turning into a member of me on as we communicate’s title are Dr. Mark Goldsmith, Revolution Medicine’s Chairman and Chief Authorities Officer; Dr. Steve Kelsey, our President of R&D; and Jack Anders, our Chief Financial Officer. Dr. Wei Lin, our Chief Medical Officer, shall be a part of us for the Q&A portion of as we communicate’s title.
I want to inform you that positive statements we make all through this title shall be forward-looking on account of such statements care for future events and are subject to many risks and uncertainties. Exact outcomes would possibly differ materially from these throughout the forward-looking statements. For a full dialogue of these risks and uncertainties, please consider our annual report on Kind 10-Okay and our quarterly report on Kind 10-Q which could be filed with the U.S. Securities and Alternate Price. This
Supply hyperlink
